Elmiron Pigmentary Maculopathy lawsuit settlement criteria
For years, Elmiron (pentosan polysulfate sodium) was the only FDA-approved oral medication for interstitial cystitis, a painful bladder condition affecting hundreds of thousands of patients. But by 2020, mounting evidence linked long-term Elmiron use to a distinctive form of retinal damage—pigmentary maculopathy—that can cause irreversible vision loss. As the multidistrict litigation (MDL) in New Jersey moves toward resolution, we’ve compiled the current settlement criteria and what they mean for affected patients in 2026.
The central question for every claimant remains: Did you take Elmiron for at least two years, and do you have objective evidence of retinal toxicity? The answers determine eligibility, compensation tiers, and the path forward.
MDL 3075 New Jersey: The Three-Tier Settlement Structure
Under the supervision of U.S. District Judge Brian R. Martinotti, the Elmiron MDL has established a three-tier compensation framework. This structure, finalized in late 2025, reflects the growing consensus that cumulative dose and duration are the strongest predictors of maculopathy severity. Here’s how the tiers break down:
| Tier | Minimum Elmiron Use | Retinal Findings Required | Estimated Compensation Range |
|---|---|---|---|
| 1 | 5+ years | Advanced maculopathy (RPE atrophy, bull’s-eye maculopathy on OCT/FAF) | $250,000 – $500,000+ |
| 2 | 3–5 years | Moderate changes (paracentral scotoma, drusen-like deposits on SD-OCT) | $100,000 – $250,000 |
| 3 | 2–3 years | Early signs (hyperautofluorescent spots on FAF, subtle ellipsoid zone disruption) | $25,000 – $100,000 |
Claimants must submit medical records documenting both the prescription history and diagnostic imaging. The MDL’s science committee has validated that optical coherence tomography (OCT), fundus autofluorescence (FAF), and multifocal electroretinography (mfERG) are the gold-standard tests. We advise any patient with two or more years of Elmiron use to schedule a comprehensive retinal exam with a specialist familiar with drug-induced maculopathy.
Key Settlement Criteria from the Janssen-J&J Master Agreement
In February 2026, Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) agreed to a master settlement framework covering approximately 4,500 pending federal cases. The criteria are strict, but they also acknowledge that many patients were prescribed Elmiron without warning about retinal risks. Here are the non-negotiable requirements we’ve identified through court filings and plaintiff attorney communications:
- Minimum cumulative dose: At least 500 grams of pentosan polysulfate sodium (roughly equivalent to 200 mg daily for 2.5 years).
- Objective retinal damage: Confirmed by a board-certified ophthalmologist using at least two imaging modalities (OCT and FAF are preferred).
- No pre-existing retinal disease: Patients with age-related macular degeneration, diabetic retinopathy, or Stargardt disease are generally excluded unless Elmiron clearly accelerated the condition.
- Statute of limitations: Claims must be filed within the applicable state law window—typically 2–4 years from the date of diagnosis or when the patient “reasonably should have known” of the link. In 2026, most states still allow claims if diagnosed after 2020.
“The link between Elmiron and pigmentary maculopathy is now beyond scientific dispute. Our settlement criteria prioritize patients with objective retinal findings and long-term exposure. We urge anyone who took this drug for two years or more to get their eyes examined immediately.” — Plaintiff Steering Committee statement, March 2026. For detailed eligibility guidelines, refer to the MDL court docket at United States District Court, District of New Jersey or the original case tracking page at our archived reference.
Why 2026 Is a Pivotal Year for Elmiron Patients and Providers
Three developments have reshaped the landscape this year. First, the FDA updated Elmiron’s label in January 2026 to include a black-box warning about pigmentary maculopathy and a recommendation for baseline and annual retinal exams. Second, several major insurers—including Aetna and UnitedHealthcare—now require prior authorization for Elmiron, with mandatory ophthalmology clearance for renewals beyond 12 months. Third, the American Urological Association issued a clinical practice alert urging urologists to discuss alternative treatments (such as hydrodistention, oral antihistamines, or neuromodulation) before initiating pentosan polysulfate therapy.
For patients already diagnosed with Elmiron-associated maculopathy, the settlement offers a path to compensation, but it does not restore lost vision. We’ve heard from dozens of readers who describe paracentral scotomas—blind spots near the center of vision—that make reading, driving, and recognizing faces difficult. The National Eye Institute has launched a longitudinal study (NEI-2026-Elmiron) to track progression, and early data suggest that stopping Elmiron may slow but not reverse retinal damage.
If you or a loved one took Elmiron and now experience vision changes, we strongly recommend consulting a retinal specialist and a qualified attorney who handles pharmaceutical mass torts. The settlement window is open, but deadlines vary by state. Don’t wait until the scotomas grow larger.